Introduction
Lyme borreliosis (LB) is the most common tick-borne disease in the North-Eastern part of the United States of America and in Europe in zones of temperate climate [259] . LB is caused by spirochetes of the Borrelia burgdorferi sensu lato (s.l.) group [32] . In the Netherlands, the number of LB cases appears to be on the rise, from 100 per 100.000 inhabitants in 2005 to 134 per 100.000 inhabitants in 2009 [106] .
Similarly, the number of visits to Dutch general practitioners (GPs) for tick bites rose from 371 per 100.000 in 2001 to 446 and 564 in 2005 and 2009 respectively. Recently, the Dutch ministry of Health has asked for concerted action on ticks and LB and asked for the development of a nation-wide collaborative effort between medical and scientific institutes focusing on LB to improve LB care and research in the Netherlands.
Diagnosis and treatment of early localized LB in the Netherlands is mostly done by
GPs, but in case of atypical localized or disseminated disease patients are often referred to medical specialists. According to international guidelines and the recently updated Dutch national guideline, objective clinical findings of early localized LB include erythema migrans (EM) and objective clinical findings of disseminated LB include Borrelia lymphocytoma, multiple EM, Lyme arthritis, Lyme carditis, Lyme neuroborreliosis (LNB) amongst other more rare manifestations [1, 49, 253, 298] . Acrodermatitis chronica atrophicans (ACA) is usually referred to as late LB. In case of an EM, which is pathognomonic for LB, no further testing is recommended since EM can precede the antibody response [22, 261] . In contrast, serological testing of antibodies against B. burgdorferi s.l. in serum is required to confirm the diagnosis of disseminated LB. When appropriate, the diagnosis of disseminated LB can be further supported by evidence from additional diagnostics, including culture and PCR of B. burgdorferi s.l. on skin, synovial fluid or cerebrospinal fluid (CSF) or suggestive histopathological findings.
Although the prognosis of LB after recommended antibiotic treatment is good and microbiological failure appears to be an infrequent event as discussed elsewhere [298] , patients may experience long lasting and debilitating subjective symptoms despite recommended antibiotic treatment. This condition has been referred to as post-treatment Lyme borreliosis syndrome or post Lyme disease syndrome (PTLBS or PLDS) [49, 298] , and randomized controlled trials did not show substantial or long-lasting beneficial effects of additional antibiotic treatment compared to placebo [74, 124, 131, 141] .
With the available serological tests it is difficult to differentiate between active and past B. burgdorferi s.l. infection and 4-8 % of the Dutch population has detectable antibodies against B. burgdorferi s.l. [186] . Therefore, it is not recommended to test patients with subjective symptoms without objective clinical findings compatible with LB. Nonetheless, approximately 70 % of the serological tests ordered by GPs are from such patients (see reference [48] and chapter 2). To establish a diagnosis in a patient presenting with subjective symptoms, with a history of tick bites and/or antibodies against B. burgdorferi s.l. -previously treated or not treated for LB -can be a challenge for physicians. On one hand, misdiagnosis of LB can lead to (multiple) antibiotic courses, without effect, but with (serious) side effects or a delay in identification and management of the actual underlying cause of the complaints [181] . On the other hand, when the clinical presentation is less clear or when diagnostic tests are not performed as, or when, they should be, a missed diagnosis could result in prolonged or progressive illness.
Therefore, in an attempt to offer better care for patients suspected of LB, we have initiated the Amsterdam Multidisciplinary Lyme borreliosis Center (AMLC). At the AMLC, various medical specialists, including infectious diseases specialists, neurologists, dermatologists and rheumatologists, collaborate to establish a diagnosis in the referred patient -either LB or an alternative diagnosis -and treat accordingly. In this report, we describe the characteristics of the first 200 adult patients who were referred to the AMLC.
Materials and methods

The AMLC
The AMLC is located at the outpatient clinic of the Academic Medical Center (AMC) of the University of Amsterdam in the Netherlands. The AMLC is open to referral of patients by GPs from the Amsterdam region and medical specialist from all over the Netherlands. Referrals were accepted -after being centrally judged by an infectious disease specialist (JH or MvV) -when there was a suspicion of LB, either based on the described symptoms or signs or the results of previous diagnostic tests, or when the referring physician specifically requested referral. 
Consecutive retrospective case series and classifications
Case record forms from patients, which were referred between January 2011 and April 2013, were retrospectively reviewed (see below) using standardized forms.
Information on (pre-visit) diagnostic test results, medical history, objective clinical findings, subjective symptoms and previous treatment was recorded and analyzed using the SPSS (version 21) software. Based on this information, patients were classified into different categories: early localized LB or disseminated LB if patients were not previously treated (Table 1A) , and persistent B. burgdorferi s.l. infection or PTLBS if patients were previously treated (Table 1B) -Subjective symptoms only 8 -Antibodies against B. burgdorferi s.l.
-Non-documented LB episode in the past 9 or a relation between the onset of symptoms and a tick bite Patients not fulfilling these criteria were classified as no LB. Other evident explanations were excluded in patients fulfilling one of these criteria. Definite cases have a low risk, probable cases a low to intermediate risk and questionable cases a high risk of being misclassified. For a more detailed description and explanation, see the Material and Method section. 1 With clinical judgment, (repeated) serology and/or skin biopsies for PCR or culture it should be possible to distinguish a probable early localized LB from a non-LB related skin manifestation. 2 If duration of symptoms was less than 6 months, cases were classified as early disseminated LB. If duration of symptoms was more than 6 months or it was defined as ACA, which is usually classified as late LB, cases were classified as late disseminated LB. 3 Based on Stanek et al (http://www.eucalb.com), which is in line with the guideline from the Dutch institute for healthcare improvement (CBO) (http://www.diliguide.nl/document/1314) and include Borrelia lymphocytoma, multiple EM, Lyme arthritis, Lyme carditis and Lyme neuroborreliosis and ACA. 4 As determined in serum by a B. burgdorferi s.l. C6 EIA (IgM/IgG, Immunetics) and/or immunoblot (either IgM and/or IgG) (Mikrogen). 5 B. burgdorferi s.l. culture or PCR and/or suggestive histopathologic findings. 6 These include atypical skin lesions, polyarthritis without involvement of large joints, conduction disorders of the heart other than AV-nodal conduction disorders or neurologic symptoms which could be attributed to LB other than a meningoradiculitis, meningoencephalitis or -polyradiculitis. 7 Based on the European Federation of Neurological Societies guidelines by Mygland et al. 8 These include nonspecific symptoms, such as widespread musculoskeletal pain (arthralgia or myalgia), paresthesia or complaints of cognitive impairment with or without fatigue. 8 LB episode in the past reported by patient, not witnessed by a physician. 9 With clinical judgment, (repeated) serology and/or skin biopsies for PCR or culture it should be possible to distinguish a probable early localized LB from a non-LB related skin manifestation. LB: Lyme borreliosis; EM: erythema migrans; CSF: cerebrospinal fluid; AI: antibody index; LNB: Lyme neuroborreliosis; NA: not applicable. 
Results
Of the patients referred to the AMLC, most were referred by GPs (n=162, 81 %) (Table 2) . Fatigue was the most reported complaint, i.e. by 141 (71 %) patients.
Other common reported symptoms included arthralgia, myalgia, paresthesia and headache (Table 2) . Skin lesions were the most reported objective clinical finding, i.e. in 31 (16 %) patients. More than half of the patients (n=108, 54 %) had 4 Previous objective clinical findings compatible with LB, which were witnessed by a physician and were diagnosed as LB. 5 These include nonspecific symptoms, such as widespread musculoskeletal pain (arthralgia or myalgia), paresthesia or complaints of cognitive impairment with or without fatigue. 6 For a description of recommended and inappropriate treatment, see Material and Methods. 7 LB episode in the past reported by patient, not witnessed by a physician. 8 As determined in serum by a B. burgdorferi s.l. C6 EIA (IgM/IgG, Immunetics) and/or immunoblot (either IgM and/or IgG) (Mikrogen). LB: Lyme borreliosis; NA: not applicable; PTLBS: Post-treatment LB syndrome.
symptoms that were present for more than one year at the time of presentation at the AMLC, of which only three had objective clinical findings that were progressive over time. Prior to referral to the AMLC, for the majority of patients serological testing was performed and approximately half of the patients had received antibiotic treatment based on a suspicion of LB (Table 2) .
A B. burgdorferi s.l. C6 EIA on serum as part of the AMLC's diagnostic work-up was done in 168 (84 %) patients and was considered positive in 66 tested sera (40 % of tested sera) (Supplementary Table 1 ). In the remaining 32 patients, the treating specialist at the AMLC deemed additional testing unnecessary, based on a low a priori chance of having LB or previous serological test results (Table 2 ). For many patients immunoblots had been performed prior to referral to the AMLC. Therefore, an immunoblot was done only in 74 (37 %) patients, of which 28 (38 % of tested sera) were positive or indeterminate (Supplementary Table 1 ). A total of 20 PCRs on skin biopsies, synovial fluid and CSF were done to strengthen or confirm the diagnosis of EM, ACA, Lyme arthritis or LNB. In addition, 29 lumbar punctures to detect specific intrathecal antibody production -by C6 EIA -and pleocytosis in CSF were performed to confirm or rule out LNB (Supplementary Table 1 ). We also tested blood samples of 29 patients -either on the patients' explicit request or because patients had a reported positive PCR blood test from a commercial laboratory prior to referral -using our clinically validated PCR -and found no positives (data not shown).
A graphical summary of the referral process and the analysis at the AMLC is shown in Figure 1A . Based on the criteria shown in Table 1 we concluded that 120 (60 %) patients did not have LB (Table 3 ). In 43 of these patients an alternative diagnosis was established (Supplementary Table 2 ), among which for example seven patients with osteoarthritis. Patients were also diagnosed with HIVinfection, polymyalgia rheumatica or multiple sclerosis, amongst other diagnoses.
An active form of LB not previously treated with antibiotics was diagnosed in 31 (16 %) patients, of which only 12 (6 %) were classified as definite LB, including 5 EM, 2 multiple EM, 1 Lyme arthritis, 1 LNB and 3 ACA ( Figure 1B ). In addition, we classified 6 patients with probable LB, including 3 cases with skin lesion(s) -2 atypical EM and 1 atypical multiple EM -and 3 LNB cases supported by pleocytosis in CSF and B. burgdorferi s.l. antibodies in serum (not in CSF). The remaining 13 LB patients were classified as questionable LB. The most reported symptoms in patients with questionable LB were fatigue, arthralgia, paresthesia, myalgia and headache. In 10 patients with questionable LB a tick bite related to the onset of the symptoms was reported and in the other three the patients reported a non-documented and untreated EM in the past.
From the 200 referred patients, 104 received prior antibiotic treatment. Of these patients, 34 (17 %) were diagnosed with PTLBS. We classified 22 patients (11 %) as probable PTLBS, meeting the criteria of the published case definition [253] , and 12 patients (6 %) as having questionable PTLBS (Table 3) Prior to the onset of these symptoms, the patient had been treated for an EM with doxycycline for 10 days, which was followed by a peripheral facial nerve paresis that had resolved over time. These three patients received antibiotic retreatment at the AMLC and clinically improved. In the twelve patients with questionable persistent B. burgdorferi s.l. infection the most reported symptoms were fatigue (n=8, 67 %), arthralgia (n=7, 58 %), paresthesia (n=6, 50 %), headache (n=6, 50 %) and myalgia (n=4, 33 %). In eight of the patients with questionable persistent B. burgdorferi s.l. infection, previous antibiotic treatment was regarded as inappropriate, because treatment was either too short or because patients had taken calcium or other supplements, which could have lowered absorption of tetracyclines from the intestine. The remaining four patients in the questionable persistent B. burgdorferi s.l. infection category reported progressive subjective symptoms after recommended treatment for a documented LB episode and no alternative explanation was evident. 6 (6 %) Other antibiotic treatment >1 month 5 6 (6 %) Sums of percentages per group may exceed 100 % due to rounding. 1 Patients could have reported multiple symptoms. 2 EIA/ELISA or EIA/ELISA and immunoblot. 3 Other nonrecommended B. burgdorferi s.l. tests include PCR on blood, dark-field microscopy live-blood analysis, lymphocyte transformation test and reduced expression of CD57 on mononuclear cells. Tests were considered positive by the (commercial) laboratory that performed the test. 4 May be combined with other antibiotic treatment. 5 May include: amoxicillin, atovaquone, azithromycin, ceftriaxone, ciprofloxacin, larithromycin, metronidazole. LB: Lyme borreliosis; bid: twice a day; ELISA: enzyme-linked immunosorbent assay; EIA: enzyme immunoassay.
Antibiotic treatment was given to 50 patients (25 %) by physicians at the AMLC, which included 27 of the 31 patients with early localized or disseminated LB. The remaining four patients had already started with antibiotic therapy, initiated by the referring physician. All patients with probable and questionable persistent B. burgdorferi s.l. infection (n=15) were treated with antibiotics. Finally, eight patients retrospectively classified as having no LB or PTLBS received antibiotic treatment at the AMLC.
Limited information on follow-up -several weeks to months -was available for only 98 (49 %) patients, making it insufficient for a thorough analysis on follow-up.
Nonetheless, we compared the follow-up data from patients with objective clinical findings compatible with or reminiscent of LB -i.e. patients with definite or probable LB and probable persisting B. burgdorferi s.l. infection -to that of patients with merely subjective symptoms -i.e. questionable LB and questionable persisting B. burgdorferi s.l. infection. In addition, we analyzed the follow-up data of both probable and questionable PTLBS patients. From 17 out of 21 patients with objective clinical findings compatible with or reminiscent of LB follow-up data was available. All of these 17 patients improved. In contrast, from 17 out of 25 questionable cases follow-up data was available and only 8 (47 %) reported improvement. In addition, of 17 out of 34 cases with PTLBS follow-up was data available -since these were usually referred back to the GP -and 15 out of these 17 patients (88 %) reported improvement.
Classification is based on the criteria and definitions shown in Tables 1 and 2 Tables 1 and 2. 4 One LNB, with pleocytosis but without B. burgdorferi s.l. antibody production in CSF, and one MEM. 5 Two late LNB, with pleocytosis but without B. burgdorferi s.l. antibody production in CSF. 6 
Discussion
In this retrospective case series, we classified 200 patients that were referred to our multidisciplinary LB referral clinic. The relatively low number of patients with LB in our study may reflect the societal concerns on LB diagnostics and treatment, the difficulty of excluding LB from the differential diagnosis, lack of awareness of the current national guidelines by the referring physicians or the lack of power to discriminate between a past and active infection with current serological tests. In addition, the low number of active B. burgdorferi s.l. infections among patients referred to the AMLC could be caused by previous referral to (multiple) other medical specialists, extensive testing on LB and antibiotic treatment prior to consultation ( classification should not be confused with 'chronic Lyme disease', which is a misnomer describing patients with chronic subjective symptoms which are attributed to LB, but that is in fact a heterogeneous group as previously described [113, 172] .
Although incomplete and limited, our follow-up analysis showed that antibiotic treatment resulted more often in improvement in patients with objective clinical findings compatible with or reminiscent of LB compared to patients in which only subjective symptoms were present. In future studies we will strive for more accurate and complete follow-up over a longer period of time, which will be facilitated in the near future by a multi-center prospective study assessing the risk of, and the risk factors for, developing persisting symptoms after treated LB. In addition, once the number of well-defined (definite and probable) LB cases increases, we will perform multiple logistic regression analysis to identify negative and/or positive predictors for LB.
To conclude, LB is an infectious disease to which specific objective clinical findings have been attributed. However, LB is invariably linked to a wide range of subjective symptoms, limited diagnostic test options, as well as poor treatment options and outcomes. This affects the use of diagnostic tests for, and treatment of, LB by physicians. In the current study we have used established, and have proposed new, criteria to categorize patient populations at LB referral centers.
Using these criteria, we show that we were able to exclude LB in many cases, to establish alternative diagnoses for a significant group of patients and to categorize most of the patients into distinct classifications. Using the currently available diagnostic tests, for some patients -especially questionable LB and questionable persisting B. burgdorferi s.l. infection cases -it is difficult to determine whether these patients indeed had a symptomatic B. burgdorferi s.l. infection. Future tests might be able to better distinguish between past and active B. burgdorferi s.l.
infections and could thus partially resolve these issues and guide antibiotic treatment. Until these tests are developed, validated and widely available, physicians with both experience with, and affinity for, LB should determine the likelihood of an active infection with B. burgdorferi s.l. in each individual patient.
The benefits of a tertiary referral center for LB -such as the AMLC -are that this evaluation is done in a multidisciplinary and systematic manner by experienced specialists, it can initiate and engage in basic and clinical research on LB and it will uncover alternative diagnoses. Thus, tertiary LB referral centers are in direct interest of LB (suspected) patients.
